Influence of genotype at the low density lipoprotein (LDL) receptor gene locus on the clinical phenotype and response to lipid-lowering drug therapy in heterozygous familial hypercholesterolaemia

Atherosclerosis

Volumn 136, Issue 1, 1998, Pages 175-185

  Sun, Xi Ming ^a   Patel, Dilip D ^a   Knight, Brian L ^a   Soutar, Anne K ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Coronary artery disease; LDL receptor activity; Lymphoblasts; Mutation

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; COLESTIPOL; COLESTYRAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; SIMVASTATIN;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LYMPHOCYTE CULTURE; MALE; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR GENE;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; CHOLESTYRAMINE; COLESTIPOL; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PHENOTYPE; RECEPTORS, LDL; SIMVASTATIN;

EID: 0031825099     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00181-0     Document Type: Article

References (23)

1. Goldstein JL, Hobbs H, Brown MS. Familial Hypercholesterolaemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The Metabolic and Molecular Bases of Inherited Disease, vol. II. New York: McGraw-Hill, 1995:1215-1250.
2. Hobbs H.H., Brown M.S., Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat. 1:1992;445-466.
3. Myant N.B. Familial defective apolipoprotein B-100: a review, including some comparisons with familial hypercholesterolaemia (published erratum appears in Atherosclerosis 1994;105:253). Atherosclerosis. 104:1993;1-18.
4. Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Br Med J. 303:1991;893-896.
5. Thompson G.R., Seed M., Niththyananthan S., McCarthy S., Thorogood M. Genotypic and phenotypic variation in familial hypercholesterolemia. Arteriosclerosis. 9(1):1989;75-80.
6. Naoumova R.P., Marais A.D., Mountney J., Firth J.C., Rendell N.B., Taylor G.W., Thompson G.R. Plasma mevalonic acid, an index of cholesterol synthesis in vivo and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis. 119:1996;203-213.
7. Leitersdorf E., Eisenberg S., Eliav O., Friedlander Y., Berkman N., Dann E.J., Landsberger D., Sehayek E., Meiner V., Wurm M., Bard J.-M., Fruchart J.-C., Stein Y. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation. 87(Suppl III):1993;35-44.
8. Jeenah M., September S., Graadt van Roggen F., de Villiers W., Seftel H., Marais D. Influence of specific mutations at the LDL-receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolaemia. Atherosclerosis. 98:1993;51-58.
9. Karayan L., Qiu S.Q., Betard C., Dufour R., Roederer G., Minnich A., Davignon J., Genest J. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ('French Canadian mutation') of the LDL receptor gene. Arterioscler Thromb. 14:1994;1258-1263.
10. Leren T.P., Hjermann I. Is responsiveness to lovastatin in familial hypercholesterolaemia heterozygotes influenced by the specific mutation in the low-density lipoprotein receptor gene? Eur J Clin Invest. 25:1995;967-973.
11. Vuorio A.F., Ojala J.P., Sarna S., Turtola H., Tikkanen M.J., Kontula K. Heterozygous familial hypercholesterolaemia: The influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med. 237:1995;43-48.
12. Thompson G.R., Maher V.M., Matthews S., Kitano Y., Neuwirth C., Shortt M.B., Davies G., Rees A., Mir A., Prescott R.J., de Feyter P., Henderson A. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 45:1995;811-816.
13. Sun X-M, Patel DD, Knight BL, Soutar AK, with the Familial Hypercholesterolaemia Regression Study Group. Comparison of the genetic defect with LDL-receptor activity in cultured cells from patients with a clinical diagnosis of heterozygous familial hypercholesterolaemia. Arterioscler Thromb Vasc Biol, in press.
14. Moorjani S., Roy M., Torres A., Betard C., Gagne C., Lambert M., Brun D., Davignon J., Lupien P. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol and expression of coronary heart disease in homozygous familial hypercholesterolaemia. Lancet. 341:1993;1303-1306.
15. Koivisto P.V.I., Koivisto U.-M., Kovanen P.T., Gylling H., Miettinen T.A., Kontula K. Deletion of exon 15 of the LDL receptor gene is associated with a mild form of familial hypercholesterolemia-FH-Espoo. Arterioscler Thromb. 13:1993;1680-1688.
16. Kotze M.J., de Villiers W.J., Steyn K., Kriek J.A., Marais A.D., Langenhoven E., Herbert J.S., Graadt van Roggen J.F., Van der Westhuyzen D.R., Coetzee G.A. Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb. 13:1993;1460-1468.
17. Tonstad S., Leren T.P., Sivertsen M., Ose L. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vasc Biol. 15:1995;1009-1014.
18. Ferrieres J., Lambert J., Lussiercacan S., Davignon J. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation. 92:1995;290-295.
19. Friedlander Y., Leitersdorf E. Influence of apolipoprotein E genotypes on plasma lipid and lipoprotein concentrations: Results from a segregation analysis in pedigrees with molecularly defined familiar hypercholesterolemia. Genet Epidemiol. 13:1996;159-177.
20. Carmena R., Lussiercacan S., Roy M., Minnich A., Lingenhel A., Kronenberg F., Davignon J. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect. Arterioscler Thromb Vasc Biol. 16:1996;129-136.
21. Sudhof T.C., Goldstein J.L., Brown M.S., Russell D.W. The LDL receptor gene: a mosaic of exons shared with different proteins. Science. 228:1985;815-822.
22. Mol M.J., Stuyt P.M., Demacker P.N., Stalenhoef A.F. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia. Neth J Med. 36:1990;182-190.
23. Lestavel-Dellatre S., Benhamamouch S., Agnani G., Luc G., Bard J.M., Brousseau T., Billardon C., Kusnierz J.P., De Gennes J.L., Fruchart J.C., Clavey V. Evidence of non-deficient low-density lipoprotein receptor patients in a pool of subjects with clinical familial hypercholesterolemia profile. Metabolism. 43:1994;397-402.